Centauri Therapeutics starting with £24m financing
Antimicrobial resistance specialist Centauri Therapeutics Ltd has closed a £24m Series A round to identify novel therapeutic candidates using the Alphamer technology.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Entries by Thomas Gabrielczyk
Curve Therapeutics in US$1.7bn deal with MSD
/in News/by Thomas GabrielczykCurve Therapeutics has inked a contract with US pharma giant Merck & Co. (MSD) to screen novel small molecule drug candidates against five MSD targets.
Newton Biocapital launches new NBC III fund
/in News/by Thomas GabrielczykNewton Biocapital has launched a new life sciences fund with initial capital commitments of 50m and a target size of 150m.
New funds to boost European life sciences
/in News/by Thomas GabrielczykEuropean investment firm LSP has closed its European life sciences fund LSP at 1 bn. Additionally, a 10bn fund of funds was greenlighted at the EU Council in Paris.
Aicuris licences antisense RNA know-how from Hybridize Therapeutics
/in News/by Thomas GabrielczykAiCuris will pay up to 100m to Dutch Hybridize Therapeutics BV for the development of antisense RNA therapeutics that stop BK viraemia in renal transplant patients.
BioNTech collaborates with AGC Biologics
/in News/by Thomas GabrielczykAGC Biologics supports BioNTech’s manufacturing of an Omicron-based vaccine with plasmids for in vitro transcription.
EU Council confirms European Scale-up Initiative
/in News/by Thomas GabrielczykEU Members States agreed on Tuesday to launch the pan-European Scale-up Initiative, which is aimed to provide 10bn for late-state tech companies.
Viennese Ribbon Biolabs closes 18m Series A financing
/in News/by Thomas GabrielczykRibbon Biolabs has cashed in 18m in Series A financing led by Hadean Ventures
mRNA specalist Ethris raises $26m in Series B financing
/in News/by Thomas GabrielczykGerman mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
BioNTech and Pfizer evaluate Omicron-specific vaccine
/in News/by Thomas GabrielczykPfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.